MMMargaret M. Matthews

Margaret M. Matthews

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Margaret M. Matthews has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Systematic Review: The Psychosocial Impacts of Autism-Related Genetic Testing

    by Ben Curran Wills, Margaret M. Matthews, Josephine Johnston, Isabel Bolo, Ruth Ottman, Paul S. Appelbaum


  • Open Access

    Patients’ Information Needs for Informed Consent to Participate in First‐in‐Human Pig Kidney Xenotransplant Clinical Trials: A Mixed Methods Study

    by Elisa J. Gordon, Michael K. Gusmano, Jessica Gacki‐Smith, Hannah L. Brooks, Margaret M. Matthews, Dahlya Manning, Joseph Leventhal, Karen J. Maschke

    Background: Transplant programs preparing to initiate first‐in‐human pig kidney xenotransplant clinical trials must be especially careful when obtaining participants’ informed consent. Little is known about the kind of information patients want for making an informed decision about trial participation. Methods: We conducted semi‐structured telephone interviews with waitlisted kidney transplant patients about information needs regarding participating in a first‐in‐human pig kidney xenotransplant trial, which guided development of a prototype consent form. Subsequent usability testing interviews sought patient feedback on the consent form. We analyzed qualitative data by thematic analysis and quantitative data by descriptive statistics. Results: Twenty‐eight patients participated in semi‐structured interviews; 16 patients participated in usability testing interviews. Most interview participants were male (68%, 56%), White (54%, 56%), or Black (36%, 31%), respectively. Interview participants identified five types of information needs: (1) the potential for infection contraction and transmission; (2) risks, benefits, and impact of xenotransplant trials; (3) xenotransplant clinical trial and recipient experience; (4) clinical trial logistics; and (5) the pig and its kidney. Usability testing participants suggested adding details to the prototype. Participants’ preparedness to make a decision about participating in a xenotransplant trial increased after reviewing the prototype (12.5% vs. 31.3%, n.s.). Conclusion: We identified multiple unique types of information patients desired to make informed decisions about pig kidney xenotransplant trial participation. Transplant programs initiating xenotransplant trials should be prepared to address patients’ information needs to optimize informed decision‐making for trial participation. The prototype consent form may support a patient‐centered approach to informed consent.


  • Open Access

    Transplant Patients’ Perceptions About Participating in First‐in‐Human Pig Kidney Xenotransplant Clinical Trials: A Mixed Methods Study

    by Elisa J. Gordon, Karen J. Maschke, Jessica Gacki‐Smith, Hannah L. Brooks, Margaret M. Matthews, Karen Traboulsi, Dahlya Manning, Joseph Leventhal, Michael K. Gusmano

    First‐in‐human pig xenotransplant clinical trials may soon begin, which raises ethical concerns about patients’ decision‐making to participate in such trials. We assessed kidney transplant candidates’ attitudes and hypothetical decision‐making about participating in xenotransplant trials through semi‐structured telephone interviews and an online survey. We analyzed qualitative data by thematic analysis and quantitative data by descriptive statistics. Twenty‐eight patients participated in interviews; 142 patients participated in the survey. Most interview and survey respondents were male (68%, 56%), White (54%, 61%), or Black (36%, 22%). Although interview participants appreciated xenotransplantation research's potential to advance science, they expressed concerns about infection transmission and graft function. Few survey respondents were willing to participate in a pig kidney trial to test the safety of pig kidneys (12.6%) or pig kidney function (16.9%). Interview participants would be more likely to participate in a first‐in‐human pig kidney trial if receiving a human kidney was unlikely and their health status declined. Willingness would also depend on how long the pig kidney would function. Most interview participants were receptive to long‐term monitoring, but not to family monitoring. Transplant programs planning xenotransplant trials should anticipate these types of concerns for optimizing human subject protections and conducting a robust informed consent process.


  • Adjunctive Tai Chi in Geriatric Depression With Comorbid Arthritis: A Randomized, Controlled Trial

    by Shilpa Srinivasan, Lawrence P. Reagan, James W. Hardin, Margaret Matthews, Elizabeth Leaphart, Claudia A. Grillo, Michele Neese, Angela Johnson, Joyce Gossard, Stephanie Chapman, et al.